Sodium arsenite down-regulates the expression of X-linked inhibitor of apoptosis protein via translational and post-translational mechanisms in hepatocellular carcinoma

Biochemical and Biophysical Research Communications

Volumn 422, Issue 4, 2012, Pages 721-726

  Chen, Hong ^a   Hao, Yuqing ^a   Wang, Lijing ^a   Jia, Dongwei ^a   Ruan, Yuanyuan ^a   Gu, Jianxin ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

IRES; Sodium arsenite; Ubiquitin proteasomal degradation; XIAP

Indexed keywords

ARSENITE SODIUM; PROTEASOME; UBIQUITIN; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DATA ANALYSIS; DOSE RESPONSE; DOWN REGULATION; ENZYMATIC DEGRADATION; ENZYME DEGRADATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN SYNTHESIS; TRANSLATION REGULATION;

ARSENITES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME INHIBITORS; HUMANS; LIVER NEOPLASMS; PROTEIN BIOSYNTHESIS; RIBOSOMES; SODIUM COMPOUNDS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84862277836     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.05.066     Document Type: Article

References (35)

1. Greten T.F., Manns M.P., Korangy F. Immunotherapy of HCC. Rev. Recent Clin. Trials 2008, 3:31-39.
2. Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J. Gastroenterol. 2009, 15:513.
3. Deveraux Q.L., Reed J.C. IAP family proteins - suppressors of apoptosis. Genes Dev. 1999, 13:239-252.
4. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell 2002, 9:459-470.
5. Holcik M., Korneluk R.G. Functional characterization of the X-linked inhibitor of apoptosis (XIAP) internal ribosome entry site element: role of La autoantigen in XIAP translation. Mol. Cell. Biol. 2000, 20:4648-4657.
6. Schile A.J., Garcia-Fernandez M., Steller H. Regulation of apoptosis by XIAP ubiquitin-ligase activity. Genes Dev. 2008, 22:2256-2266.
7. Yang Y., Fang S., Jensen J.P., Weissman A.M., Ashwell J.D. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000, 288:874-877.
8. Deveraux Q.L., Leo E., Stennicke H.R., Welsh K., Salvesen G.S., Reed J.C. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J. 1999, 18:5242-5251.
9. Shin H., Okada K., Wilkinson J.C., Solomon K.M., Duckett C.S., Reed J.C., Salvesen G.S. Identification of ubiquitination sites on the X-linked inhibitor of apoptosis protein. Biochem. J. 2003, 373:965-971.
10. Zhang S., Ding F., Luo A., Chen A., Yu Z., Ren S., Liu Z., Zhang L. XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics. Cancer Biol. Ther. 2007, 6:973-980.
11. Ramp U., Krieg T., Caliskan E., Mahotka C., Ebert T., Willers R., Gabbert H.E., Gerharz C.D. XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum. Pathol. 2004, 35:1022-1028.
12. Mansouri A., Zhang Q., Ridgway L.D., Tian L., Claret F.X. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncol. Res. 2003, 13:399-404.
13. Akyurek N., Ren Y., Rassidakis G.Z., Schlette E.J., Medeiros L.J. Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas. Cancer 2006, 107:1844-1851.
14. Shi Y.H., Ding W.X., Zhou J., He J.Y., Xu Y., Gambotto A.A., Rabinowich H., Fan J., Yin X.M. Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology 2008, 48:497-507.
15. Liu B., Pan S., Dong X., Qiao H., Jiang H., Krissansen G.W., Sun X. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci. 2006, 97:675-681.
16. Chiu H.W., Ho Y.S., Wang Y.J. Arsenic trioxide induces autophagy and apoptosis in human glioma cells in vitro and in vivo through downregulation of survivin. J. Mol. Med. (Berl.) 2011, 89:927-941.
17. Griffin R.J., Williams B.W., Koonce N.A., Bischof J.C., Song C.W., Asur R., Upreti M. Vascular disrupting agent arsenic trioxide enhances thermoradiotherapy of solid tumors. J. Oncol. 2012, 2012:934918.
18. Fei M., Lu M., Wang Y., Zhao Y., He S., Gao S., Ke Q., Liu Y., Li P., Cui X., Shen A., Cheng C. Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization. Med. Oncol. 2009, 26:178-185.
19. Othumpangat S., Kashon M., Joseph P. Sodium arsenite-induced inhibition of eukaryotic translation initiation factor 4E (eIF4E) results in cytotoxicity and cell death. Mol. Cell. Biochem. 2005, 279:123-131.
20. Li Z., Wang H., Zong H., Sun Q., Kong X., Jiang J., Gu J. Downregulation of beta1,4-galactosyltransferase 1 inhibits CDK11(p58)-mediated apoptosis induced by cycloheximide. Biochem. Biophys. Res. Commun. 2005, 327:628-636.
21. Hao Y., Kong X., Ruan Y., Gan H., Chen H., Zhang C., Ren S., Gu J. CDK11p46 and RPS8 associate with each other and suppress translation in a synergistic manner. Biochem. Biophys. Res. Commun. 2011, 407:169-174.
22. Holcik M., Lefebvre C., Yeh C., Chow T., Korneluk R.G. A new internal-ribosome-entry-site motif potentiates XIAP-mediated cytoprotection. Nat. Cell Biol. 1999, 1:190-192.
23. Holcik M., Sonenberg N. Translational control in stress and apoptosis. Nat. Rev. Mol. Cell Biol. 2005, 6:318-327.
24. Marienfeld C., Yamagiwa Y., Ueno Y., Chiasson V., Brooks L., Meng F., Patel T. Translational regulation of XIAP expression and cell survival during hypoxia in human cholangiocarcinoma. Gastroenterology 2004, 127:1787-1797.
25. Yang J., Hong Y., Wang W., Wu W., Chi Y., Zong H., Kong X., Wei Y., Yun X., Cheng C., Chen K., Gu J. HSP70 protects BCL2L12 and BCL2L12A from N-terminal ubiquitination-mediated proteasomal degradation. FEBS Lett. 2009, 583:1409-1414.
26. Ciechanover A. N-terminal ubiquitination. Methods Mol. Biol. 2005, 301:255-270.
27. Dan H.C., Sun M., Kaneko S., Feldman R.I., Nicosia S.V., Wang H.G., Tsang B.K., Cheng J.Q. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein. J. Biol. Chem. 2004, 279:5405-5412.
28. Mann K.K., Colombo M., Miller W.H. Arsenic trioxide decreases AKT protein in a caspase-dependent manner. Mol. Cancer Ther. 2008, 7:1680-1687.
29. Kashkar H. X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow promise. Clin. Cancer Res. 2010, 16:4496-4502.
30. Ramachandiran S., Cain J., Liao A., He Y., Guo X., Boise L.H., Fu H., Ratner L., Khoury H.J., Bernal-Mizrachi L. The Smac mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac. Leuk. Res. 2012, 36:784-790.
31. Edison N., Reingewertz T.H., Gottfried Y., Lev T., Zuri D., Maniv I., Carp M.J., Shalev G., Friedler A., Larisch S. Peptides mimicking the unique ARTS-XIAP binding site promote apoptotic cell death in cultured cancer cells. Clin. Cancer Res. 2012, 18:2569-2578.
32. Chawla-Sarkar M., Bae S.I., Reu F.J., Jacobs B.S., Lindner D.J., Borden E.C. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 2004, 11:915-923.
33. McManus D.C., Lefebvre C.A., Cherton-Horvat G., St-Jean M., Kandimalla E.R., Agrawal S., Morris S.J., Durkin J.P., Lacasse E.C. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 2004, 23:8105-8117.
34. Jiang C., Tan T., Yi X.P., Shen H., Li Y.X. Lentivirus-mediated shRNA targeting XIAP and survivin inhibit SW1990 pancreatic cancer cell proliferation in vitro and in vivo. Mol. Med. Rep 2011, 4:667-674.
35. Ma J.J., Chen B.L., Xin X.Y. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma. Eur. J. Obstet. Gynecol. Reprod. Biol. 2009, 146:222-226.